our research
our research
No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis
Symptom Burden on Ocrelizumab: A Longitudinal Study (SymBOLS)
Some patients with multiple sclerosis (MS) receiving ocrelizumab (OCR) report worsening symptoms toward the end of the 6-month infusion cycle (‘wearing off ’). The objective of our study was to comprehensively assess changes in symptom burden across 2 consecutive OCR infusion cycles.
ACAPELLA: Real - World Experience with Ocrelizumab Year Six Data
For presentation at CMSC 2023
We sought to evaluate the frequency of AEs in a real-world population of patients receiving OCR including those with characteristics outside the inclusion parameters of the phase II & III trials, focusing on infections and malignancies.
ACAPELLA: Hypogammaglobulinemia in Ocrelizumab-Treated Patients, 6 Year Data
For presentation at CMSC 2023
As part of the ACAPELLA trial ( a prospective study assessing OCR-associated adverse events in a real-world population), we evaluated the impact of OCR on IgG levels and JCV index. This data set reflects results collected through March 1, 2023.
ACAPELLA: Real - World Experience with Ocrelizumab Year Five Data
For presentation at ECTRIMS 2022
We sought to evaluate the frequency of AEs in a real-world population of patients receiving OCR including those with characteristics outside the inclusion parameters of the phase II & III trials, focusing on infections and malignancies.
ACAPELLA: Hypogammaglobulinemia and JCV Status in Ocrelizumab - Treated Patients, 2022 Update
For presentation at ECTRIMS 2022
As part of the ACAPELLA trial ( a prospective study assessing OCR-associated adverse events in a real-world population), we evaluated the impact of OCR on IgG levels and JCV index. This data set reflects results collected through September 1, 2022.
ACAPELLA: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Five Data
As part of the ACAPELLA trial ( a prospective study assessing OCR-associated adverse events in a real-world population), we evaluated the impact of OCR on IgG levels and JCV index. This data set reflects results collected through March 1, 2022.
ACAPELLA: Real-World Experience with Ocrelizumab, Year Five Data
We sought to evaluate the frequency of AEs in a real-world population of patients receiving OCR including those with characteristics outside the inclusion parameters of the phase II & III trials, focusing on infections and malignancies.
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
We sought to provide data regarding B and T-cell mediated responses to SARS-CoV-2 vaccination in ocrelizumab-treated patients, and to determine what variables correlate with vaccine immunogenicity. We hypothesized that patients without a humoral response to SARS-CoV-2 vaccination would still have intact T-cell responses.
ACAPELLA: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, 2021 Update
As part of the ACAPELLA trial (a prospective study assessing OCR-associated adverse events in a real-world population), we evaluated the impact of OCR on IgG levels and JCV titers as well as any correlation between IgG levels and infection risk. This dataset reflects results collected through September 1, 2021.
ACAPELLA: B-Cell Reconstitution in Ocrelizumab-Treated Patients, 2021 Update
As part of the ACAPELLA trial (a prospective study assessing OCR-associated adverse events in a real-world population) we sought to describe the incidence and degree of B-cell repletion in our patients treated with OCR and to evaluate any correlation between CD19+ cell count, demographics, AEs, and breakthrough disease.
ACAPELLA: Real-World Experience with Ocrelizumab, Year Four Data
We sought to evaluate the frequency of AEs in a real-world population of patients receiving OCR with characteristics outside the inclusion parameters of the phase II & III trials, focusing on infections and malignancies.
ACAPELLA: Real-World Experience with Ocrelizumab, Year Three Data
We sought to examine the frequency of AEs in a real-world population receiving OCR with characteristics outside the inclusion parameters of the phase II & III trials, focusing on infections requiring antibiotics and neoplasms. This dataset reflects results three years after FDA approval of OCR.
ACAPELLA: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Three Data
We evaluated the impact of OCR on immunoglobulin levels and JCV titers, as well as any correlation between IgG levels and infection risk. This dataset reflects results collected through March 15, 2020.
ACAPELLA: B-cell Repletion in Ocrelizumab-Treated Patients, Year Three Data
We sought to describe the incidence and degree of B-cell repletion in our patients treated with OCR and to evaluate and correlation between CD19+ cell count, demographics, AEs, and breakthrough disease.
ACAPELLA: Real-World Experience with Ocrelizumab, Year Two Data
We sought to examine the frequency of AEs in a real-world population receiving OCR with characteristics outside the inclusion parameters of the phase II & III trials, focusing on infections requiring antibiotics and neoplasms. This dataset reflects results two years after FDA approval of OCR.
ACAPELLA: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients
As part of the ACAPELLA trial (a prospective study assessing OCR-associated adverse events in a real-world population, see poster DXT63), we evaluated the impact of OCR on immunoglobulin levels and JCV titers over time as well as any correlation between IgG levels and infection risk. In patients with low IgG, we evaluated immune function through measurement of specific antibody titers. This dataset reflects results collected through March 15, 2019.
Psoriasis Exacerbation during Ocrelizumab Therapy for Relapsing Multiple Sclerosis: A Case Report
The objective is to describe a case of preexisting psoriasis with acute disseminated psoriasis following treatment with Ocrevus.
ACAPELLA: Real World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive Multiple Sclerosis
We sought to compare the frequency of adverse events (AEs) in our population of patients on Ocrevus with the clinical trial population (CTP), and to determine if AEs were more frequent in subjects with age and/or EDSS outside the inclusion criteria of the Phase III trials. This data set reflects results at one year.
PML and IRIS: Between a Rock and a Hard Place
The objective of the study was to describe the clinical course, radiologic findings, treatment, and outcomes of 6 patients with natalizumab-associated PML and IRIS treated at The Elliot Lewis Center from 2012 to 2016.
Characterizing the Natalizumab “Wearing Off” Effect
The objective of the study was to characterize the prevalence and clinical features of the natalizumab Wearing Off Effect in our patient population.
To Pee or Not To Pee? The Utility of Bladder Scans in Multiple Sclerosis
The objective of the project was to evaluate the frequency of asymptomatic urinary retention and UTIs to assess the utility of PVR measurement in the office setting and to examine the correlation of urinary symptoms with the presence of spinal cord lesions.
Understanding Concepts Important to Natalizumab Patients: A Qualitative Interview Study
The objective of the project was to understand concepts that are the most meaningful to MS patients treated with natalizumab and how patients weigh the benefits/risks of treatment.